首页 > 最新文献

Liver Cancer最新文献

英文 中文
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial) 评估晚期肝细胞癌患者术前伦伐替尼治疗有效性和安全性的多中心2期试验(LENS-HCC试验)
IF 13.8 1区 医学 Q1 Medicine Pub Date : 2023-11-28 DOI: 10.1159/000535514
A. Ichida, J. Arita, E. Hatano, S. Eguchi, A. Saiura, Hiroaki Nagano, J. Shindoh, Masaji Hashimoto, Nobuyuki Takemura, K. Taura, Y. Sakamoto, Yu Takahashi, Y. Seyama, Yasuharu Sasaki, Kohei Uemura, N. Kokudo, Kiyoshi Hasegawa
Introduction: The phase III REFLECT trial demonstrated that lenvatinib was superior to sorafenib in terms of progression-free survival (PFS), time to progression, and objective response rate (ORR) for patients with unresectable hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of preoperative lenvatinib therapy for patients with oncologically or technically unresectable HCC. Methods: In this multicenter single-arm phase II trial, patients with advanced HCC and factors suggestive of a poor prognosis (macroscopic vascular invasion, extrahepatic metastasis, or multinodular tumors) were enrolled. Patients with these factors, even with technically resectable HCC, were defined as oncologically unresectable because of the expected poor prognosis after surgery. After 8 weeks of lenvatinib therapy, the patients were assessed for resectability, and tumor resection was performed if the tumor was considered technically resectable. The primary endpoint was the surgical resection rate. The secondary endpoints were the macroscopic curative resection rate, overall survival (OS), ORR, PFS, and the change in the indocyanine green retention rate at 15 minutes as measured before and after lenvatinib therapy. The trial was registered with the Japan Registry of Clinical Trials (s031190057). Results: Between July 2019 and January 2021, 49 patients (42 oncologically unresectable patients and 7 technically unresectable patients) from 11 centers were enrolled. The ORR was 37.5% based on mRECIST and 12.5% based on RECIST version 1.1. Thirty-three patients underwent surgery (surgical resection rate: 67.3%) without perioperative mortality. The surgical resection rate was 76.2% for oncologically unresectable patients and 14.3% for technically unresectable patients. The 1-year OS rate and median PFS were 75.9% and 7.2 months, respectively, with a median follow-up period of 9.3 months. Conclusions: The relatively high surgical resection rate seen in this study suggests the safety and feasibility of lenvatinib therapy followed by surgical resection for patients with oncologically or technically unresectable HCC.
简介III期REFLECT试验表明,在不可切除肝细胞癌(HCC)患者的无进展生存期(PFS)、进展时间和客观反应率(ORR)方面,来伐替尼优于索拉非尼。本研究评估了来伐替尼术前治疗肿瘤学或技术上无法切除的HCC患者的有效性和安全性。研究方法在这项多中心单臂II期试验中,研究人员招募了晚期HCC患者和预后不良的提示因素(大血管侵犯、肝外转移或多结节肿瘤)患者。具有这些因素的患者,即使在技术上可切除HCC,也被定义为肿瘤学上不可切除的患者,因为预计术后预后较差。来伐替尼治疗8周后,对患者的可切除性进行评估,如果认为肿瘤在技术上可切除,则进行肿瘤切除。主要终点是手术切除率。次要终点为大体治愈切除率、总生存期(OS)、ORR、PFS以及来伐替尼治疗前后15分钟吲哚青绿保留率的变化。该试验已在日本临床试验注册中心注册(S031190057)。试验结果2019年7月至2021年1月期间,来自11个中心的49名患者(42名肿瘤无法切除的患者和7名技术无法切除的患者)入组。基于 mRECIST 的 ORR 为 37.5%,基于 RECIST 1.1 版的 ORR 为 12.5%。33名患者接受了手术(手术切除率:67.3%),无围手术期死亡。肿瘤学上无法切除的患者手术切除率为76.2%,技术上无法切除的患者手术切除率为14.3%。1年的OS率和中位PFS分别为75.9%和7.2个月,中位随访期为9.3个月。结论:手术切除率相对较高:本研究中相对较高的手术切除率表明,对于肿瘤学或技术上无法切除的HCC患者,来伐替尼治疗后再进行手术切除是安全可行的。
{"title":"A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial)","authors":"A. Ichida, J. Arita, E. Hatano, S. Eguchi, A. Saiura, Hiroaki Nagano, J. Shindoh, Masaji Hashimoto, Nobuyuki Takemura, K. Taura, Y. Sakamoto, Yu Takahashi, Y. Seyama, Yasuharu Sasaki, Kohei Uemura, N. Kokudo, Kiyoshi Hasegawa","doi":"10.1159/000535514","DOIUrl":"https://doi.org/10.1159/000535514","url":null,"abstract":"Introduction: The phase III REFLECT trial demonstrated that lenvatinib was superior to sorafenib in terms of progression-free survival (PFS), time to progression, and objective response rate (ORR) for patients with unresectable hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of preoperative lenvatinib therapy for patients with oncologically or technically unresectable HCC. Methods: In this multicenter single-arm phase II trial, patients with advanced HCC and factors suggestive of a poor prognosis (macroscopic vascular invasion, extrahepatic metastasis, or multinodular tumors) were enrolled. Patients with these factors, even with technically resectable HCC, were defined as oncologically unresectable because of the expected poor prognosis after surgery. After 8 weeks of lenvatinib therapy, the patients were assessed for resectability, and tumor resection was performed if the tumor was considered technically resectable. The primary endpoint was the surgical resection rate. The secondary endpoints were the macroscopic curative resection rate, overall survival (OS), ORR, PFS, and the change in the indocyanine green retention rate at 15 minutes as measured before and after lenvatinib therapy. The trial was registered with the Japan Registry of Clinical Trials (s031190057). Results: Between July 2019 and January 2021, 49 patients (42 oncologically unresectable patients and 7 technically unresectable patients) from 11 centers were enrolled. The ORR was 37.5% based on mRECIST and 12.5% based on RECIST version 1.1. Thirty-three patients underwent surgery (surgical resection rate: 67.3%) without perioperative mortality. The surgical resection rate was 76.2% for oncologically unresectable patients and 14.3% for technically unresectable patients. The 1-year OS rate and median PFS were 75.9% and 7.2 months, respectively, with a median follow-up period of 9.3 months. Conclusions: The relatively high surgical resection rate seen in this study suggests the safety and feasibility of lenvatinib therapy followed by surgical resection for patients with oncologically or technically unresectable HCC.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":13.8,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139224239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study 因贝伐单抗不良事件而放弃贝伐单抗对接受阿特珠单抗加贝伐单抗治疗的不可切除肝细胞癌患者的影响:IMbrave150Ⅲ期研究的探索性分析
IF 13.8 1区 医学 Q1 Medicine Pub Date : 2023-11-28 DOI: 10.1159/000535501
Masatoshi Kudo, Kaoru Tsuchiya, Y. Shao, R. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, R. Take, Kyoko Yamada, T. Asakawa, Yuki Nakagawa, Masafumi Ikeda
Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs). Methods: Patients in IMbrave150 who were randomized to atezolizumab + bevacizumab and received treatment for ≥6 months (to reduce immortal time bias) were included in group A-1 if bevacizumab had ever been skipped due to bevacizumab AESIs or to group A-2 otherwise. Efficacy analyses included overall survival (OS) and progression-free survival (PFS) by whether bevacizumab was skipped (group A-1 vs A-2). PFS was evaluated per independent review facility (IRF)–assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and HCC-modified RECIST (IRF-HCC mRECIST). Safety was also evaluated. Results: Of the 210 patients who received ≥6 months of atezolizumab + bevacizumab, 69 were assigned to group A-1 and 141 to A-2. At data cutoff (August 20, 2020), hazard ratio (HR) for OS was 1.04 (95% CI: 0.64, 1.69) for group A-1 vs A-2. HR for PFS was 1.07 (95% CI: 0.74, 1.55) per IRF-assessed RECIST 1.1 and 1.10 (95% CI: 0.76, 1.59; 15.5 vs 9.7 months) per IRF-HCC mRECIST for group A-1 vs A-2. Safety profiles for atezolizumab and bevacizumab were largely similar between groups. More group A-1 patients had grade 3/4 adverse events. A separate analysis investigating the impact of immortal time bias in patients who received ≥3 months of atezolizumab + bevacizumab supported the appropriateness of the ≥6-month landmark analysis. Discussion/Conclusion: Efficacy was similar between patients who skipped bevacizumab due to bevacizumab AESIs and those who did not. Although this comparison was nonrandomized and exploratory, results suggest that skipping bevacizumab due to bevacizumab AESIs did not considerably impact the efficacy and safety of atezolizumab + bevacizumab.
简介IMbrave150Ⅲ期研究将阿特珠单抗+贝伐单抗确立为不可切除肝细胞癌(HCC)患者的全球标准治疗方案。这项探索性分析研究了因贝伐单抗特别关注不良事件(AESIs)而中断贝伐单抗治疗的影响。 研究方法IMbrave150中随机接受阿特珠单抗+贝伐珠单抗治疗且治疗时间≥6个月(以减少不死时间偏倚)的患者,如果曾因贝伐珠单抗AESI而跳过贝伐珠单抗,则纳入A-1组,否则纳入A-2组。疗效分析包括总生存期(OS)和无进展生存期(PFS),按是否跳过贝伐珠单抗(A-1 组与 A-2 组)进行分析。PFS根据独立审查机构(IRF)评估的《实体瘤反应评估标准》(RECIST)1.1版和HCC修正版RECIST(IRF-HCC mRECIST)进行评估。此外,还对安全性进行了评估。 结果:在接受阿特珠单抗+贝伐单抗治疗≥6个月的210名患者中,69人被分配到A-1组,141人被分配到A-2组。在数据截止日(2020年8月20日),A-1组与A-2组的OS危险比(HR)为1.04(95% CI:0.64,1.69)。A-1组与A-2组的PFS的HR分别为1.07(95% CI:0.74,1.55)和1.10(95% CI:0.76,1.59;15.5个月与9.7个月)。阿特珠单抗和贝伐珠单抗的安全性在各组之间基本相似。更多的A-1组患者出现了3/4级不良事件。一项单独的分析调查了接受atezolizumab+贝伐珠单抗治疗≥3个月的患者中永恒时间偏差的影响,结果支持≥6个月的标志性分析的适当性。 讨论/结论:因贝伐珠单抗AESI而放弃贝伐珠单抗的患者与未放弃贝伐珠单抗的患者疗效相似。尽管这种比较是非随机的、探索性的,但结果表明,因贝伐珠单抗 AESI 而跳过贝伐珠单抗并不会对阿特珠单抗+贝伐珠单抗的疗效和安全性产生重大影响。
{"title":"Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study","authors":"Masatoshi Kudo, Kaoru Tsuchiya, Y. Shao, R. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, R. Take, Kyoko Yamada, T. Asakawa, Yuki Nakagawa, Masafumi Ikeda","doi":"10.1159/000535501","DOIUrl":"https://doi.org/10.1159/000535501","url":null,"abstract":"Introduction: The Phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs). Methods: Patients in IMbrave150 who were randomized to atezolizumab + bevacizumab and received treatment for ≥6 months (to reduce immortal time bias) were included in group A-1 if bevacizumab had ever been skipped due to bevacizumab AESIs or to group A-2 otherwise. Efficacy analyses included overall survival (OS) and progression-free survival (PFS) by whether bevacizumab was skipped (group A-1 vs A-2). PFS was evaluated per independent review facility (IRF)–assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and HCC-modified RECIST (IRF-HCC mRECIST). Safety was also evaluated. Results: Of the 210 patients who received ≥6 months of atezolizumab + bevacizumab, 69 were assigned to group A-1 and 141 to A-2. At data cutoff (August 20, 2020), hazard ratio (HR) for OS was 1.04 (95% CI: 0.64, 1.69) for group A-1 vs A-2. HR for PFS was 1.07 (95% CI: 0.74, 1.55) per IRF-assessed RECIST 1.1 and 1.10 (95% CI: 0.76, 1.59; 15.5 vs 9.7 months) per IRF-HCC mRECIST for group A-1 vs A-2. Safety profiles for atezolizumab and bevacizumab were largely similar between groups. More group A-1 patients had grade 3/4 adverse events. A separate analysis investigating the impact of immortal time bias in patients who received ≥3 months of atezolizumab + bevacizumab supported the appropriateness of the ≥6-month landmark analysis. Discussion/Conclusion: Efficacy was similar between patients who skipped bevacizumab due to bevacizumab AESIs and those who did not. Although this comparison was nonrandomized and exploratory, results suggest that skipping bevacizumab due to bevacizumab AESIs did not considerably impact the efficacy and safety of atezolizumab + bevacizumab.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":13.8,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139217114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second-Line Treatment after Failure of Immune Check Point Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy? 肝细胞癌免疫检查点抑制剂治疗失败后的二线治疗:酪氨酸激酶抑制剂、免疫治疗的再试验,还是局部治疗?
1区 医学 Q1 Medicine Pub Date : 2023-11-13 DOI: 10.1159/000534303
Sang Youn Hwang, Sangjune L. Lee, Hongqun Liu, Samuel S. Lee
Background: Immune check point inhibitor (ICI)-based therapy such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab became mainstream first-line systemic treatment in advanced hepatocellular carcinoma (HCC) patients since remarkably superior efficacy of ICI-based therapy compared to tyrosine kinase inhibitors (TKI) was reported in two recent randomized controlled trials (RCTs) (IMbrave150, HIMALAYA). However, the optimal second-line therapy after treatment failure of first-line ICI-based therapy remains unknown as no RCT has examined this issue. Summary: Therefore, at present most clinicians are empirically treating patients with TKIs or retrial of ICI or locoregional treatment (LRT) modality such as transarterial therapy, radiofrequency ablation, and radiation therapy in this clinical setting without solid evidence. In this review, we will discuss current optimal strategies for second-line treatment after the failure of first-line ICI-based therapy by reviewing published studies and ongoing prospective trials. Key Messages: Clinicians should consider carefully whether to treat the patients with TKI, other ICI-based therapy, or LRT in this situation by considering several factors including liver function reserve, performance status, adverse events of previous therapy, and presence of lesion that can consider LRT such as oligoprogression, vascular invasion, etc. In the meantime, we await the results of ongoing prospective trials to elucidate the best management options.
背景:最近的两项随机对照试验(rct) (IMbrave150, HIMALAYA)报道了基于免疫检查点抑制剂(ICI)的治疗方法,如atezolizumab加贝伐单抗或durvalumab加tremelimumab成为晚期肝细胞癌(HCC)患者的主流一线全身治疗,因为基于ICI的治疗方法与酪氨酸激酶抑制剂(TKI)相比显着优于TKI。然而,一线ci治疗失败后的最佳二线治疗仍然未知,因为没有RCT研究过这个问题。摘要:因此,目前大多数临床医生都是经验性地治疗TKIs患者,或者在没有确凿证据的情况下再试验ICI或局部区域治疗(LRT)方式,如经动脉治疗、射频消融和放射治疗。在这篇综述中,我们将通过回顾已发表的研究和正在进行的前瞻性试验,讨论目前一线ici治疗失败后二线治疗的最佳策略。关键信息:在这种情况下,临床医生应考虑肝功能储备、功能状态、既往治疗的不良事件以及是否存在可考虑LRT的病变(如少进展、血管侵犯等)等因素,慎重考虑是否采用TKI、其他基于ci的治疗或LRT。与此同时,我们等待正在进行的前瞻性试验的结果,以阐明最佳的管理选择。
{"title":"Second-Line Treatment after Failure of Immune Check Point Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","authors":"Sang Youn Hwang, Sangjune L. Lee, Hongqun Liu, Samuel S. Lee","doi":"10.1159/000534303","DOIUrl":"https://doi.org/10.1159/000534303","url":null,"abstract":"Background: Immune check point inhibitor (ICI)-based therapy such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab became mainstream first-line systemic treatment in advanced hepatocellular carcinoma (HCC) patients since remarkably superior efficacy of ICI-based therapy compared to tyrosine kinase inhibitors (TKI) was reported in two recent randomized controlled trials (RCTs) (IMbrave150, HIMALAYA). However, the optimal second-line therapy after treatment failure of first-line ICI-based therapy remains unknown as no RCT has examined this issue. Summary: Therefore, at present most clinicians are empirically treating patients with TKIs or retrial of ICI or locoregional treatment (LRT) modality such as transarterial therapy, radiofrequency ablation, and radiation therapy in this clinical setting without solid evidence. In this review, we will discuss current optimal strategies for second-line treatment after the failure of first-line ICI-based therapy by reviewing published studies and ongoing prospective trials. Key Messages: Clinicians should consider carefully whether to treat the patients with TKI, other ICI-based therapy, or LRT in this situation by considering several factors including liver function reserve, performance status, adverse events of previous therapy, and presence of lesion that can consider LRT such as oligoprogression, vascular invasion, etc. In the meantime, we await the results of ongoing prospective trials to elucidate the best management options.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 Lenvatinib联合派姆单抗治疗不可切除肝细胞癌的1b期研究:研究116的扩展分析
1区 医学 Q1 Medicine Pub Date : 2023-11-13 DOI: 10.1159/000535154
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Background: Treatment with lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). Objective: This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. Methods: 100 Patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS) and investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). Results: ORR was 43.0% (95% CI 33.1% to 53.3%) and median DOR was 17.1 months (95% CI 6.9 to 19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4 to 9.8 months) and 20.4 months (95% CI 14.4 to 25.9 months), respectively. No treatment-emergent ADAs were detected. Conclusion: Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting.
背景:lenvatinib治疗(体重≥60kg的患者剂量为12mg /天;在开放标签1b期研究116/KEYNOTE-524(主要分析数据截止日期:2019年10月31日)中,体重60 kg的患者,剂量为8mg /天)加派姆单抗200mg每3周一次,在一线不可切除的肝细胞癌(uHCC)患者中显示出抗肿瘤活性和可控的安全性。中位随访:10.6个月)。目的:该分析(更新数据截止日期:2021年3月31日)报告了17个月额外随访时间的疗效结果。方法:100例uHCC患者纳入初步分析(中位随访时间:27.6个月)。终点包括总生存期(OS)和研究者评估的无进展生存期(PFS)、客观缓解率(ORR)和反应持续时间(DOR)。通过3个月和9个月的最佳反应进行OS的里程碑式分析。还测量了派姆单抗抗药抗体(ADAs)和浓度(截止日期:2020年8月7日)。结果:ORR为43.0% (95% CI 33.1% ~ 53.3%),中位DOR为17.1个月(95% CI 6.9 ~ 19.3个月)。中位PFS和OS分别为9.3个月(95% CI为7.4至9.8个月)和20.4个月(95% CI为14.4至25.9个月)。未检测到治疗后出现的ADAs。结论:结果显示lenvatinib + pembrolizumab在一线治疗uHCC患者具有持续的治疗效果。
{"title":"A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116","authors":"Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet","doi":"10.1159/000535154","DOIUrl":"https://doi.org/10.1159/000535154","url":null,"abstract":"Background: Treatment with lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). Objective: This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. Methods: 100 Patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS) and investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). Results: ORR was 43.0% (95% CI 33.1% to 53.3%) and median DOR was 17.1 months (95% CI 6.9 to 19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4 to 9.8 months) and 20.4 months (95% CI 14.4 to 25.9 months), respectively. No treatment-emergent ADAs were detected. Conclusion: Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of liver fibrosis severity on oncological prognosis in hepatocellular carcinoma 肝纤维化严重程度对肝癌预后的影响
1区 医学 Q1 Medicine Pub Date : 2023-10-31 DOI: 10.1159/000533857
Koya Yasukawa, Akira Shimizu, Koji Kubota, Tsuyoshi Notake, Kiyotaka Hosoda, Hikaru Hayashi, Yuji Soejima
Introduction: Cirrhosis is deemed to be a contributing factor to the postoperative recurrence of hepatocellular carcinoma (HCC), however, the precise impact of liver fibrosis on both cancer-specific prognosis remains unclear. This investigation sought to elucidate the effect of liver fibrosis severity on the cancer-specific prognosis. Methods: A total of 524 consecutive patients were included. Recurrence-free survival (RFS) and disease-specific survival (DSS) were compared according to fibrosis stage. Moreover, postoperative outcomes were subjected to analysis in cohorts of patients with F0 and F1-3, as well as in those with F1-3 and F4, who were carefully matched for background factors. Results: The five-year RFS exhibited a significantly worse outcome in the F4 group compared to other stages of fibrosis [5-year RFS: F0 (46.6%), F1-3 (33.1%) and F4 (23.5%), P=0.03 (F0 vs. F1-3) and P<0.01 (F1-3 vs. F4)]. Additionally, the five-year DSS also presented a significantly worse prognosis in the F4 group (5-year DSS: F0 (82.9%), F1-3 (73.6%) and F4 (57.4%), P=0.04 (F0 vs. F1-3) and P<0.01 (F1-3 vs. F4)]. In multivariate analysis, fibrosis 1, 2, 3, and 4 stage (compared with F0) (HR: 1.70, 1.81, 1.89, and 3.99, 95 % CI: 1.10–1.99, 1.39–2.22, 1.41–2.55, and 2.25–5.01, P=0.022, P=0.008, P<0.001, and P<0.001, respectively) was independent risk factor for RFS. After matched analysis, both RFS and DSS exhibited significantly worse prognoses in the presence of more advanced fibrosis. There was a significantly higher incidence of multiple recurrences in the F4 group than the F1–3 group, and a number of recurrences were observed both in the same hepatic segment as the resected side and in the contralateral lobe in F4 group. Discussion/Conclusion: The hazard and recurrence pattern of HCC signifies that the prognosis could potentially be poor, as the hepatic fibrosis likely owing to a higher hepatocarcinogenic potential, even in the absence of progression to cirrhotic condition. The risk of de novo recurrence may also increase with the progression of this fibrosis.
肝硬化被认为是肝细胞癌(HCC)术后复发的一个促进因素,然而,肝纤维化对两种癌症特异性预后的确切影响尚不清楚。本研究旨在阐明肝纤维化严重程度对癌症特异性预后的影响。方法:共纳入524例连续患者。根据纤维化分期比较无复发生存期(RFS)和疾病特异性生存期(DSS)。此外,对F0和F1-3组患者以及F1-3和F4组患者的术后结果进行分析,并仔细匹配背景因素。结果:F4组5年RFS预后明显差于其他纤维化分期[5年RFS: F0 (46.6%), F1-3 (33.1%), F4 (23.5%), P=0.03 (F0 vs. F1-3), P<0.01 (F1-3 vs. F4)]。此外,F4组5年DSS预后也明显较差(5年DSS: F0(82.9%)、F1-3(73.6%)、F4 (57.4%), P=0.04 (F0 vs. F1-3)、P<0.01 (F1-3 vs. F4))。在多因素分析中,纤维化1、2、3和4期(与F0期相比)(HR: 1.70、1.81、1.89和3.99,95% CI: 1.10-1.99、1.39-2.22、1.41-2.55和2.25-5.01,P=0.022, P=0.008, P<0.001和P<0.001)是RFS的独立危险因素。在匹配分析后,RFS和DSS在存在更晚期纤维化时表现出明显更差的预后。F4组多发复发发生率明显高于F1-3组,且F4组与切除侧同一肝段及对侧肝叶均有多发复发。讨论/结论:HCC的危险和复发模式表明其预后可能很差,因为肝纤维化可能是由于较高的肝癌潜在致癌性,即使在没有肝硬化进展的情况下。新发复发的风险也可能随着纤维化的进展而增加。
{"title":"Impact of liver fibrosis severity on oncological prognosis in hepatocellular carcinoma","authors":"Koya Yasukawa, Akira Shimizu, Koji Kubota, Tsuyoshi Notake, Kiyotaka Hosoda, Hikaru Hayashi, Yuji Soejima","doi":"10.1159/000533857","DOIUrl":"https://doi.org/10.1159/000533857","url":null,"abstract":"Introduction: Cirrhosis is deemed to be a contributing factor to the postoperative recurrence of hepatocellular carcinoma (HCC), however, the precise impact of liver fibrosis on both cancer-specific prognosis remains unclear. This investigation sought to elucidate the effect of liver fibrosis severity on the cancer-specific prognosis. Methods: A total of 524 consecutive patients were included. Recurrence-free survival (RFS) and disease-specific survival (DSS) were compared according to fibrosis stage. Moreover, postoperative outcomes were subjected to analysis in cohorts of patients with F0 and F1-3, as well as in those with F1-3 and F4, who were carefully matched for background factors. Results: The five-year RFS exhibited a significantly worse outcome in the F4 group compared to other stages of fibrosis [5-year RFS: F0 (46.6%), F1-3 (33.1%) and F4 (23.5%), P=0.03 (F0 vs. F1-3) and P<0.01 (F1-3 vs. F4)]. Additionally, the five-year DSS also presented a significantly worse prognosis in the F4 group (5-year DSS: F0 (82.9%), F1-3 (73.6%) and F4 (57.4%), P=0.04 (F0 vs. F1-3) and P<0.01 (F1-3 vs. F4)]. In multivariate analysis, fibrosis 1, 2, 3, and 4 stage (compared with F0) (HR: 1.70, 1.81, 1.89, and 3.99, 95 % CI: 1.10–1.99, 1.39–2.22, 1.41–2.55, and 2.25–5.01, P=0.022, P=0.008, P<0.001, and P<0.001, respectively) was independent risk factor for RFS. After matched analysis, both RFS and DSS exhibited significantly worse prognoses in the presence of more advanced fibrosis. There was a significantly higher incidence of multiple recurrences in the F4 group than the F1–3 group, and a number of recurrences were observed both in the same hepatic segment as the resected side and in the contralateral lobe in F4 group. Discussion/Conclusion: The hazard and recurrence pattern of HCC signifies that the prognosis could potentially be poor, as the hepatic fibrosis likely owing to a higher hepatocarcinogenic potential, even in the absence of progression to cirrhotic condition. The risk of de novo recurrence may also increase with the progression of this fibrosis.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135808406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis 免疫检查点抑制剂对乙型肝炎病毒感染的肝细胞癌患者生存率有利:一项系统回顾和荟萃分析
1区 医学 Q1 Medicine Pub Date : 2023-10-30 DOI: 10.1159/000534446
Qi Du, Jia Yuan, Zhenggang Ren
Background Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness for advanced hepatocellular carcinoma (HCC). However, the discrepancy in the efficacy of ICIs in HCC patients with distinct etiologies has not been systematically validated. Methods PubMed, MEDLINE, EMBASE, clinicaltrials.gov and abstracts from ASCO and ESMO conferences were searched for eligible trials that explored the impact of etiology factor on the ICI treatment in HCC patients. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS), as well as the pooled odds ratio (OR) of objective response rate (ORR) were calculated with stratification of hepatitis B virus (HBV), hepatitis C virus (HCV) and nonviral subgroup, and the heterogeneity between different etiological subgroup were assessed by using an interaction test. Results Eight eligible studies with a total of 5646 patients were identified from searching published articles and conference abstracts. ICI therapies were associated with significantly prolonged OS with the pooled HRs of 0.78 (95%CI 0.73-0.84, p < 0.001), 0.71 (95%CI 0.65-0.79, p < 0.001), 0.80 (95%CI 0.69-0.93, p = 0.003) and 0.87 (95%CI 0.77-0.97, p = 0.011) for the whole population, HBV subgroup, HCV subgroup and non-viral subgroup, respectively. In addition, this analysis reported a significant PFS improvement with ICI therapies with HRs of 0.78 (p = 0.004), 0.53 (p < 0.001), 0.65 (p = 0.011) and 0.81 (p = 0.107) for whole population, HBV, HCV and nonviral subgroup, respectively. The HBV-related HCC patients showed the more distinctive HRs for OS and PFS than other etiology subgroups, and this difference was significant in PFS (p for heterogeneity = 0.001) and there was a tendency of significance in OS (p for heterogeneity = 0.079). Furthermore, the ORR advantages of ICI therapies over control were also confirmed with the pooled ORs of 3.62 (p < 0.001), 3.84 (p < 0.001), 3.05 (p < 0.001) and 2.99 (p < 0.001) for whole population, HBV, HCV and nonviral subgroup, respectively (p for heterogeneity = 0.743). Conclusions ICI therapies significantly improve OS, PFS and ORR for HCC patients with different etiologies. HBV-related HCC patients could be the highlighted population to benefit from ICI treatment.
免疫检查点抑制剂(ICIs)已被证明对晚期肝细胞癌(HCC)有效。然而,在不同病因的HCC患者中,ICIs的疗效差异尚未得到系统验证。方法检索PubMed、MEDLINE、EMBASE、clinicaltrials.gov以及ASCO和ESMO会议的摘要,寻找探讨病因因素对HCC患者ICI治疗影响的符合条件的试验。对乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和非病毒亚组进行分层,计算总生存期(OS)和无进展生存期(PFS)的合并危险比(HR),以及客观缓解率(ORR)的合并优势比(OR),并通过相互作用检验评估不同病因亚组之间的异质性。结果从已发表文章和会议摘要中检索到8项符合条件的研究,共5646例患者。ICI治疗与显著延长的OS相关,合并hr为0.78 (95%CI 0.73-0.84, p <0.001), 0.71 (95%CI 0.65-0.79, p <整个人群、HBV亚组、HCV亚组和非病毒亚组分别为0.80 (95%CI 0.69-0.93, p = 0.003)、0.87 (95%CI 0.77-0.97, p = 0.011)。此外,该分析报告了ICI治疗的PFS显著改善,hr分别为0.78 (p = 0.004)和0.53 (p <整个人群、HBV、HCV和非病毒亚组分别为0.65 (p = 0.011)、0.81 (p = 0.107)。与其他病因亚组相比,hbv相关HCC患者OS和PFS的HRs更有差异,PFS差异显著(p = 0.001), OS差异有显著趋势(p = 0.079)。此外,ICI治疗的ORR优势也被证实为3.62 (p <0.001), 3.84 (p <0.001), 3.05 (p <0.001)和2.99 (p <0.001),在整个人群、HBV、HCV和非病毒亚组中分别为(p = 0.743)。结论ICI治疗可显著改善不同病因HCC患者的OS、PFS和ORR。hbv相关的HCC患者可能是受益于ICI治疗的重点人群。
{"title":"Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","authors":"Qi Du, Jia Yuan, Zhenggang Ren","doi":"10.1159/000534446","DOIUrl":"https://doi.org/10.1159/000534446","url":null,"abstract":"Background Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness for advanced hepatocellular carcinoma (HCC). However, the discrepancy in the efficacy of ICIs in HCC patients with distinct etiologies has not been systematically validated. Methods PubMed, MEDLINE, EMBASE, clinicaltrials.gov and abstracts from ASCO and ESMO conferences were searched for eligible trials that explored the impact of etiology factor on the ICI treatment in HCC patients. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS), as well as the pooled odds ratio (OR) of objective response rate (ORR) were calculated with stratification of hepatitis B virus (HBV), hepatitis C virus (HCV) and nonviral subgroup, and the heterogeneity between different etiological subgroup were assessed by using an interaction test. Results Eight eligible studies with a total of 5646 patients were identified from searching published articles and conference abstracts. ICI therapies were associated with significantly prolonged OS with the pooled HRs of 0.78 (95%CI 0.73-0.84, p < 0.001), 0.71 (95%CI 0.65-0.79, p < 0.001), 0.80 (95%CI 0.69-0.93, p = 0.003) and 0.87 (95%CI 0.77-0.97, p = 0.011) for the whole population, HBV subgroup, HCV subgroup and non-viral subgroup, respectively. In addition, this analysis reported a significant PFS improvement with ICI therapies with HRs of 0.78 (p = 0.004), 0.53 (p < 0.001), 0.65 (p = 0.011) and 0.81 (p = 0.107) for whole population, HBV, HCV and nonviral subgroup, respectively. The HBV-related HCC patients showed the more distinctive HRs for OS and PFS than other etiology subgroups, and this difference was significant in PFS (p for heterogeneity = 0.001) and there was a tendency of significance in OS (p for heterogeneity = 0.079). Furthermore, the ORR advantages of ICI therapies over control were also confirmed with the pooled ORs of 3.62 (p < 0.001), 3.84 (p < 0.001), 3.05 (p < 0.001) and 2.99 (p < 0.001) for whole population, HBV, HCV and nonviral subgroup, respectively (p for heterogeneity = 0.743). Conclusions ICI therapies significantly improve OS, PFS and ORR for HCC patients with different etiologies. HBV-related HCC patients could be the highlighted population to benefit from ICI treatment.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136067994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SAFETY AND EFFICACY OF ATEZOLIZUMAB/ BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND IMPAIRED LIVER FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS atezolizumab / bevacizumab在肝细胞癌和肝功能受损患者中的安全性和有效性:一项系统回顾和荟萃分析
1区 医学 Q1 Medicine Pub Date : 2023-10-14 DOI: 10.1159/000533991
Andrea Pasta, Francesco Calabrese, Ariel Jaffe, Sara Labanca, Simona Marenco, Giulia Pieri, Maria Corina Plaz Torres, Mario Strazzabosco, Edoardo G. Giannini
Background: Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized. Objectives: In this study, we aimed at addressing safety and efficacy of atezolizumab/bevacizumab in Child-Pugh B patients by reviewing the available data and analyzing them by meta-analysis. Methods: We compared the safety and efficacy of atezolizumab/becavizumab treatment in patients with unresectable HCC and various degrees of liver dysfunction. A total of 8 retrospective, non-randomized, cohort studies were included in this meta-analysis, for a total of 1,071 Child-Pugh A and 225 Child-Pugh B patients. The albumin-bilirubin (ALBI) grade was also used to assess liver function, when available. Results: Grade ≥3 adverse events were observed in 11.8% of Child-Pugh class A and 26.8% class B patients (p = 0.0001), with an odds ratio (OR) of 0.43 (confidence interval [CI] 0.21–0.90; p = 0.02). Progression-free survival (PFS) at both 6 months (4.90 ± 2.08 vs. 4.75 ± 2.08 months; p = 0.0004) and 12 months (8.83 ± 2.32 vs. 7.26 ± 2.33 months; p = 0.002) was lower in Child-Pugh class B patients. A trend toward a higher objective response rate (ORR) was observed in Child-Pugh class A patients (219/856, 25.6%) as compared to Child-Pugh class B patients (25/138, 18.1%; p = 0.070), while the probability of obtaining an ORR was significantly greater in Child-Pugh A patients (OR 1.79, CI 1.12–2.86; p = 0.02). Median overall survival (OS) was 16.8 ± 2.0 and 6.8 ± 3.2 months in Child-Pugh A and B patients, respectively (mean difference 9.06 months, CI 7.01–11.1, p &lt; 0.0001). Lastly, OS was longer in patients with ALBI grades 1–2 than in those with grade 3 (8.3 ± 11.4 vs. 3.3 ± 5.0 months, p = 0.0008). Conclusions: Oncological efficacy of atezolizumab/bevacizumab is moderate in Child-Pugh class B patients, and the shorter PFS and OS associated with the greater likelihood of experiencing treatment-related adverse events observed in these patients suggest great caution and individualization of treatment, possibly with the support of the ALBI grade.
& lt; b> & lt; i>背景:& lt; / i> & lt; / b>atezolizumab/bevacizumab治疗Child-Pugh B型肝细胞癌(HCC)患者的安全性和预后尚未完全确定。& lt; b> & lt; i>目标:& lt; / i> & lt; / b>在这项研究中,我们旨在通过回顾现有数据并通过荟萃分析分析来解决atezolizumab/bevacizumab在Child-Pugh B患者中的安全性和有效性。& lt; b> & lt; i>方法:& lt; / i> & lt; / b>我们比较了atezolizumab/becavizumab治疗不可切除HCC和不同程度肝功能障碍患者的安全性和有效性。本荟萃分析共纳入8项回顾性、非随机、队列研究,共纳入1071例Child-Pugh A和225例Child-Pugh B患者。当可用时,白蛋白胆红素(ALBI)分级也用于评估肝功能。& lt; b> & lt; i>结果:& lt; / i> & lt; / b>11.8%的Child-Pugh A类患者和26.8%的Child-Pugh B类患者出现≥3级不良事件(<i>p</i>= 0.0001),优势比(OR)为0.43(置信区间[CI] 0.21-0.90;& lt; i>术中;/ i>= 0.02)。6个月的无进展生存期(PFS)(4.90±2.08 vs 4.75±2.08个月;& lt; i>术中;/ i>= 0.0004)和12个月(8.83±2.32 vs. 7.26±2.33个月;& lt; i>术中;/ i>Child-Pugh B级患者= 0.002)。Child-Pugh A级患者的客观缓解率(ORR)(219/856, 25.6%)高于Child-Pugh B级患者(25/138,18.1%;& lt; i>术中;/ i>= 0.070),而Child-Pugh A患者获得ORR的概率显著更高(OR 1.79, CI 1.12-2.86;& lt; i>术中;/ i>= 0.02)。Child-Pugh A组和B组患者的中位总生存期(OS)分别为16.8±2.0和6.8±3.2个月(平均差9.06个月,CI 7.01-11.1, <i> </i>, lt;0.0001)。最后,1-2级ALBI患者的OS时间长于3级ALBI患者(8.3±11.4个月vs 3.3±5.0个月),<= 0.0008)。& lt; b> & lt; i>结论:& lt; / i> & lt; / b>在Child-Pugh B级患者中,atezolizumab/bevacizumab的肿瘤疗效是中等的,在这些患者中观察到的较短的PFS和OS与更大的发生治疗相关不良事件的可能性相关,建议非常谨慎和个性化治疗,可能需要ALBI分级的支持。
{"title":"SAFETY AND EFFICACY OF ATEZOLIZUMAB/ BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND IMPAIRED LIVER FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS","authors":"Andrea Pasta, Francesco Calabrese, Ariel Jaffe, Sara Labanca, Simona Marenco, Giulia Pieri, Maria Corina Plaz Torres, Mario Strazzabosco, Edoardo G. Giannini","doi":"10.1159/000533991","DOIUrl":"https://doi.org/10.1159/000533991","url":null,"abstract":"<b><i>Background:</i></b> Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized. <b><i>Objectives:</i></b> In this study, we aimed at addressing safety and efficacy of atezolizumab/bevacizumab in Child-Pugh B patients by reviewing the available data and analyzing them by meta-analysis. <b><i>Methods:</i></b> We compared the safety and efficacy of atezolizumab/becavizumab treatment in patients with unresectable HCC and various degrees of liver dysfunction. A total of 8 retrospective, non-randomized, cohort studies were included in this meta-analysis, for a total of 1,071 Child-Pugh A and 225 Child-Pugh B patients. The albumin-bilirubin (ALBI) grade was also used to assess liver function, when available. <b><i>Results:</i></b> Grade ≥3 adverse events were observed in 11.8% of Child-Pugh class A and 26.8% class B patients (<i>p</i> = 0.0001), with an odds ratio (OR) of 0.43 (confidence interval [CI] 0.21–0.90; <i>p</i> = 0.02). Progression-free survival (PFS) at both 6 months (4.90 ± 2.08 vs. 4.75 ± 2.08 months; <i>p</i> = 0.0004) and 12 months (8.83 ± 2.32 vs. 7.26 ± 2.33 months; <i>p</i> = 0.002) was lower in Child-Pugh class B patients. A trend toward a higher objective response rate (ORR) was observed in Child-Pugh class A patients (219/856, 25.6%) as compared to Child-Pugh class B patients (25/138, 18.1%; <i>p</i> = 0.070), while the probability of obtaining an ORR was significantly greater in Child-Pugh A patients (OR 1.79, CI 1.12–2.86; <i>p</i> = 0.02). Median overall survival (OS) was 16.8 ± 2.0 and 6.8 ± 3.2 months in Child-Pugh A and B patients, respectively (mean difference 9.06 months, CI 7.01–11.1, <i>p</i> &amp;lt; 0.0001). Lastly, OS was longer in patients with ALBI grades 1–2 than in those with grade 3 (8.3 ± 11.4 vs. 3.3 ± 5.0 months, <i>p</i> = 0.0008). <b><i>Conclusions:</i></b> Oncological efficacy of atezolizumab/bevacizumab is moderate in Child-Pugh class B patients, and the shorter PFS and OS associated with the greater likelihood of experiencing treatment-related adverse events observed in these patients suggest great caution and individualization of treatment, possibly with the support of the ALBI grade.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135803622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/β-catenin mutations Wnt/β-连环蛋白突变的人肝癌免疫微环境的两个不同特征
1区 医学 Q1 Medicine Pub Date : 2023-10-09 DOI: 10.1159/000533818
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masakatsu Tsurusaki, Takuya Nakai, Michiie Sakamoto, Kazuto Nishio, Masatoshi Kudo
Introduction Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype, their role on TME remains controversial. We aimed to clarify the heterogeneity of immunophenotype in HCC with Wnt/β-catenin mutations. Methods This study includes 152 resected HCCs; mutations in the catenin beta-1, adenomatous polyposis coli, or AXIN1, or AXIN2 genes were defined as Wnt/β-catenin mutations. With hierarchical cluster analyses, TME were classified into inflamed or non-inflamed classes based on the gene expressions associated with T-cell activation. Expression profiles of molecules related to cell differentiation and biliary-stem cell markers were compared between the TME classes to investigate whether differences in tumor traits were associated with TME. Results Forty of 152 (26.3%) HCCs carried the Wnt/β-catenin mutations. Of these, 33 were classified as non-inflamed (33/40, 82.5%) and 7 as inflamed (7/40, 17.5%). Non-inflamed class was characterized by low number of CD3+, CD4+, and CD8+ cells on immunostaining, and high mRNA expressions of AXIN2 and GLUL, which are involved in the canonical Wnt/β-catenin signaling and hepatocyte differentiation, respectively. Non-inflamed tumors showed higher enhancement on the hepatobiliary-phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) compared to inflamed tumors. HCCs classified as inflamed class are revealed to have high numbers of CD3+, CD4+, and CD8+ tumor infiltrating lymphocytes on immunostaining. This class is associated with increased expression of anti-epithelial cell adhesion molecule (EpCAM) and FOXM1 accompanied by upregulation of genes related to interferon-gamma signaling, dendritic cell migration, regulatory T cells and MDSC activation and recognized as low enhancement nodule on Gd-EOB-DTPA-enhanced MRI. Conclusion Heterogeneity of tumor traits and TME was observed in HCC with Wnt/β-catenin mutation. The potential was indicated that tumor traits and TME are determined not only by the activation of the HNF4A but also by FOXM1, both of which are downstream transcription factor of the Wnt/β-catenin signaling pathway.
免疫治疗正在成为治疗不可切除的肝细胞癌(HCC)的一种有前景的方法;抗肿瘤反应受肿瘤微环境(tumor microenvironment, TME)影响。尽管有报道称Wnt/β-连环蛋白突变会导致非炎症表型,但它们在TME中的作用仍存在争议。我们旨在阐明Wnt/β-catenin突变HCC免疫表型的异质性。方法本研究纳入152例切除的hcc;连环蛋白β- 1、大肠腺瘤性息肉病或AXIN1或AXIN2基因的突变被定义为Wnt/β-连环蛋白突变。通过分层聚类分析,根据与t细胞活化相关的基因表达将TME分为炎症或非炎症类。研究人员比较了不同TME类别中与细胞分化相关的分子和胆道干细胞标记物的表达谱,以研究肿瘤特征的差异是否与TME相关。结果152例hcc中有40例(26.3%)携带Wnt/β-catenin突变。其中33例为无炎症(33/40,82.5%),7例为炎症(7/40,17.5%)。非炎症组免疫染色CD3+、CD4+和CD8+细胞数量较少,AXIN2和GLUL mRNA高表达,这两种细胞分别参与典型的Wnt/β-catenin信号传导和肝细胞分化。与炎症肿瘤相比,非炎症肿瘤的肝胆道期钆-乙氧基苄基-二乙烯三胺(Gd-EOB-DTPA)增强磁共振成像(MRI)显示更高的增强。炎症型hcc免疫染色显示CD3+、CD4+和CD8+肿瘤浸润淋巴细胞数量高。这一类与抗上皮细胞粘附分子(EpCAM)和FOXM1的表达增加有关,并伴有与干扰素- γ信号、树突状细胞迁移、调节性T细胞和MDSC激活相关的基因上调,在gd - eob - dtpa增强MRI上被识别为低增强结节。结论Wnt/β-catenin突变HCC的肿瘤特征及TME存在异质性。这表明肿瘤性状和TME不仅由HNF4A的激活决定,也由FOXM1的激活决定,两者都是Wnt/β-catenin信号通路的下游转录因子。
{"title":"Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/β-catenin mutations","authors":"Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masakatsu Tsurusaki, Takuya Nakai, Michiie Sakamoto, Kazuto Nishio, Masatoshi Kudo","doi":"10.1159/000533818","DOIUrl":"https://doi.org/10.1159/000533818","url":null,"abstract":"Introduction Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype, their role on TME remains controversial. We aimed to clarify the heterogeneity of immunophenotype in HCC with Wnt/β-catenin mutations. Methods This study includes 152 resected HCCs; mutations in the catenin beta-1, adenomatous polyposis coli, or AXIN1, or AXIN2 genes were defined as Wnt/β-catenin mutations. With hierarchical cluster analyses, TME were classified into inflamed or non-inflamed classes based on the gene expressions associated with T-cell activation. Expression profiles of molecules related to cell differentiation and biliary-stem cell markers were compared between the TME classes to investigate whether differences in tumor traits were associated with TME. Results Forty of 152 (26.3%) HCCs carried the Wnt/β-catenin mutations. Of these, 33 were classified as non-inflamed (33/40, 82.5%) and 7 as inflamed (7/40, 17.5%). Non-inflamed class was characterized by low number of CD3+, CD4+, and CD8+ cells on immunostaining, and high mRNA expressions of AXIN2 and GLUL, which are involved in the canonical Wnt/β-catenin signaling and hepatocyte differentiation, respectively. Non-inflamed tumors showed higher enhancement on the hepatobiliary-phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) compared to inflamed tumors. HCCs classified as inflamed class are revealed to have high numbers of CD3+, CD4+, and CD8+ tumor infiltrating lymphocytes on immunostaining. This class is associated with increased expression of anti-epithelial cell adhesion molecule (EpCAM) and FOXM1 accompanied by upregulation of genes related to interferon-gamma signaling, dendritic cell migration, regulatory T cells and MDSC activation and recognized as low enhancement nodule on Gd-EOB-DTPA-enhanced MRI. Conclusion Heterogeneity of tumor traits and TME was observed in HCC with Wnt/β-catenin mutation. The potential was indicated that tumor traits and TME are determined not only by the activation of the HNF4A but also by FOXM1, both of which are downstream transcription factor of the Wnt/β-catenin signaling pathway.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135147252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Data on the Diagnosis, Treatment and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT study 亚太地区肝细胞癌的诊断、治疗和管理的真实数据:INSIGHT研究
1区 医学 Q1 Medicine Pub Date : 2023-10-09 DOI: 10.1159/000534513
Yu Ki Sim, Ming Chuen Chong, Mihir Gandhi, Yogesh Mahadev Pokharkar, Yanan Zhu, Luming Shi, Li Lequn, Chien-Hung Chen, Masatoshi Kudo, Joon Hyeok Lee, Simone I Strasser, Rawisak Chanwat, Pierce K.H. Chow
Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilized in clinical practice in the real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. Methods: Data were collected both retrospectively (planned 30% of the total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. Results: A total of 2,533 newly diagnosed HCC patients (1,052 in retrospective cohort and 1,481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia, and New Zealand, where the prevalence of hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension, and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stages, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, the presence of extrahepatic metastases or macrovascular invasion, and the use of subsequent lines of treatment were performed. Conclusion: The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs, and patient access to therapies may lead to wide geographical variations through the patient’s treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes.
& lt; b> & lt; i>简介:& lt; / i> & lt; / b>肝细胞癌(HCC)是全球第六大最常诊断的癌症,也是导致癌症死亡的第三大原因。虽然在过去的十年中,HCC的治疗模式有了快速的发展,但这些新批准的治疗方法在现实世界的临床实践中的应用程度尚不清楚。INSIGHT研究是一项由研究者发起的多地点纵向队列研究,旨在反映BRIDGE研究结束后亚太地区7年内的真实流行病学和临床实践。& lt; b> & lt; i>方法:& lt; / i> & lt; / b>从2013年1月至2019年12月,回顾性(计划占总队列规模的30%)和前瞻性(计划占70%)收集了来自9个亚太国家33个参与地点的新诊断为HCC的符合条件的患者的数据。& lt; b> & lt; i>结果:& lt; / i> & lt; / b>共纳入2533例新诊断的HCC患者(1052例为回顾性队列,1481例为前瞻性队列)。除日本、澳大利亚和新西兰外,所有国家最常见的危险因素是乙型肝炎,在这些国家,丙型肝炎和糖尿病的患病率更为普遍。INSIGHT研究报告的前三大合并症包括肝硬化、高血压和糖尿病。我们观察到不同国家和不同疾病阶段记录的一线治疗的高度异质性,这显著影响生存结果。根据病因、肿瘤特征、肝外转移或大血管侵犯的存在以及后续治疗的使用等因素进行分层。& lt; b> & lt; i>结论:& lt; / i> & lt; / b>INSIGHT研究描述了HCC的广泛临床管理实践,其中患者人口统计学,差异成本和患者获得治疗的机会可能导致患者从诊断到临床结果的整个治疗周期中存在广泛的地理差异。患者预后的高度异质性表明,需要设计和采用更稳健的临床管理策略,以带来更好的患者预后。
{"title":"Real-world Data on the Diagnosis, Treatment and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT study","authors":"Yu Ki Sim, Ming Chuen Chong, Mihir Gandhi, Yogesh Mahadev Pokharkar, Yanan Zhu, Luming Shi, Li Lequn, Chien-Hung Chen, Masatoshi Kudo, Joon Hyeok Lee, Simone I Strasser, Rawisak Chanwat, Pierce K.H. Chow","doi":"10.1159/000534513","DOIUrl":"https://doi.org/10.1159/000534513","url":null,"abstract":"<b><i>Introduction:</i></b> Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilized in clinical practice in the real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. <b><i>Methods:</i></b> Data were collected both retrospectively (planned 30% of the total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. <b><i>Results:</i></b> A total of 2,533 newly diagnosed HCC patients (1,052 in retrospective cohort and 1,481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia, and New Zealand, where the prevalence of hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension, and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stages, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, the presence of extrahepatic metastases or macrovascular invasion, and the use of subsequent lines of treatment were performed. <b><i>Conclusion:</i></b> The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs, and patient access to therapies may lead to wide geographical variations through the patient’s treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135146198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: Transforming the immune microenvironment with molecular targeted agents 肝内胆管癌的遗传/表观遗传改变与肿瘤免疫微环境:用分子靶向药物改变免疫微环境
1区 医学 Q1 Medicine Pub Date : 2023-10-04 DOI: 10.1159/000534443
Naoshi Nishida, Masatoshi Kudo
Background Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However, recent advancements in the understanding of the molecular characteristics of iCCA have opened new possibilities for molecular-targeted therapies and immunotherapy. Summary Reportedly, 9–36% of iCCA cases have an inflamed tumor immune microenvironment (TME) based on the immune gene expression signature, which is characterized by the presence of immune cells involved in anti-tumor immune responses. The majority of iCCA cases have a non-inflamed TME with a lack of effector T cells, rendering immune checkpoint inhibitors (ICIs) ineffective in these cases. Interestingly, alterations in the fibroblast growth factor receptor (FGFR2) gene and IDH1/2 gene mutations are often observed in the non-inflamed TME in iCCA. Several mechanisms have been reported for the role of driver mutations on the establishment of TME unique for iCCA. For example, IDH1/2 mutations, which cause an increase in DNA methylation, are associated with the downregulation and hypermethylation of antigen processing and presentation machineries, which may contribute to the establishment of a non-inflamed TME. Therefore, inhibitors targeting IDH1/2 may restore the DNA methylation and expression status of molecules involved in antigen presentation, potentially improving the efficacy of ICIs. FGFR inhibitors may also have the potential to modulate immunosuppressive TME by inhibiting suppressor of cytokine signaling 1 and activating the interferon-γ signaling as a consequence of inhibition of FGFR signal. From this perspective, understanding the molecular characteristics of iCCA, including the TME and driver mutations, is essential for effective application of ICIs and molecular-targeted therapies. Key Messages Combination approaches that target both the tumor and immune system hold promise for improving the outcomes of patients with iCCA. Further research and clinical trials are needed to validate these approaches and optimize the treatment strategies for iCCA.
背景肝内胆管癌(iCCA)通常在晚期诊断,导致治疗选择有限和预后不良。到目前为止,晚期iCCA的标准全身治疗是吉西他滨和顺铂的联合治疗。然而,最近对iCCA分子特征的理解取得了进展,为分子靶向治疗和免疫治疗开辟了新的可能性。据报道,9-36%的iCCA病例存在基于免疫基因表达特征的炎症性肿瘤免疫微环境(TME),其特征是存在参与抗肿瘤免疫反应的免疫细胞。大多数iCCA病例具有缺乏效应T细胞的非炎症性TME,使得免疫检查点抑制剂(ICIs)在这些病例中无效。有趣的是,在iCCA的非炎症TME中经常观察到成纤维细胞生长因子受体(FGFR2)基因和IDH1/2基因突变的改变。已经报道了驱动突变在iCCA独特的TME建立中的作用的几种机制。例如,引起DNA甲基化增加的IDH1/2突变与抗原加工和递呈机制的下调和高甲基化有关,这可能有助于建立非炎症性TME。因此,靶向IDH1/2的抑制剂可能会恢复参与抗原呈递的分子的DNA甲基化和表达状态,从而潜在地提高ICIs的疗效。FGFR抑制剂也可能通过抑制细胞因子信号1的抑制因子和激活干扰素-γ信号作为抑制FGFR信号的结果来调节免疫抑制性TME。从这个角度来看,了解iCCA的分子特征,包括TME和驱动突变,对于iCCA的有效应用和分子靶向治疗至关重要。针对肿瘤和免疫系统的联合治疗方法有望改善iCCA患者的预后。需要进一步的研究和临床试验来验证这些方法并优化iCCA的治疗策略。
{"title":"Genetic/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: Transforming the immune microenvironment with molecular targeted agents","authors":"Naoshi Nishida, Masatoshi Kudo","doi":"10.1159/000534443","DOIUrl":"https://doi.org/10.1159/000534443","url":null,"abstract":"Background Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However, recent advancements in the understanding of the molecular characteristics of iCCA have opened new possibilities for molecular-targeted therapies and immunotherapy. Summary Reportedly, 9–36% of iCCA cases have an inflamed tumor immune microenvironment (TME) based on the immune gene expression signature, which is characterized by the presence of immune cells involved in anti-tumor immune responses. The majority of iCCA cases have a non-inflamed TME with a lack of effector T cells, rendering immune checkpoint inhibitors (ICIs) ineffective in these cases. Interestingly, alterations in the fibroblast growth factor receptor (FGFR2) gene and IDH1/2 gene mutations are often observed in the non-inflamed TME in iCCA. Several mechanisms have been reported for the role of driver mutations on the establishment of TME unique for iCCA. For example, IDH1/2 mutations, which cause an increase in DNA methylation, are associated with the downregulation and hypermethylation of antigen processing and presentation machineries, which may contribute to the establishment of a non-inflamed TME. Therefore, inhibitors targeting IDH1/2 may restore the DNA methylation and expression status of molecules involved in antigen presentation, potentially improving the efficacy of ICIs. FGFR inhibitors may also have the potential to modulate immunosuppressive TME by inhibiting suppressor of cytokine signaling 1 and activating the interferon-γ signaling as a consequence of inhibition of FGFR signal. From this perspective, understanding the molecular characteristics of iCCA, including the TME and driver mutations, is essential for effective application of ICIs and molecular-targeted therapies. Key Messages Combination approaches that target both the tumor and immune system hold promise for improving the outcomes of patients with iCCA. Further research and clinical trials are needed to validate these approaches and optimize the treatment strategies for iCCA.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Liver Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1